ME vs. PBYI, ACIU, AQST, IMMP, TSVT, ALDX, XBIT, VSTM, FHTX, and RENB
Should you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include Puma Biotechnology (PBYI), AC Immune (ACIU), Aquestive Therapeutics (AQST), Immutep (IMMP), 2seventy bio (TSVT), Aldeyra Therapeutics (ALDX), XBiotech (XBIT), Verastem (VSTM), Foghorn Therapeutics (FHTX), and Renovaro (RENB). These companies are all part of the "pharmaceutical preparations" industry.
Puma Biotechnology (NASDAQ:PBYI) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability.
Puma Biotechnology has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.
Puma Biotechnology currently has a consensus target price of $7.00, indicating a potential upside of 46.14%. 23andMe has a consensus target price of $0.47, indicating a potential downside of 7.84%. Given 23andMe's stronger consensus rating and higher probable upside, equities research analysts plainly believe Puma Biotechnology is more favorable than 23andMe.
Puma Biotechnology has a net margin of 6.79% compared to Puma Biotechnology's net margin of -210.48%. 23andMe's return on equity of 35.49% beat Puma Biotechnology's return on equity.
Puma Biotechnology received 524 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 66.58% of users gave Puma Biotechnology an outperform vote while only 63.16% of users gave 23andMe an outperform vote.
Puma Biotechnology has higher earnings, but lower revenue than 23andMe. 23andMe is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 36.1% of 23andMe shares are owned by institutional investors. 22.7% of Puma Biotechnology shares are owned by company insiders. Comparatively, 27.6% of 23andMe shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Puma Biotechnology had 3 more articles in the media than 23andMe. MarketBeat recorded 13 mentions for Puma Biotechnology and 10 mentions for 23andMe. Puma Biotechnology's average media sentiment score of 0.46 beat 23andMe's score of 0.43 indicating that 23andMe is being referred to more favorably in the news media.
Summary
Puma Biotechnology beats 23andMe on 15 of the 18 factors compared between the two stocks.
Get 23andMe News Delivered to You Automatically
Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
